AbbVie Suspends Five Clinical Trials of Leukemia Therapy

AbbVie Inc., the drug company that split off from Abbott Laboratories at the start of the year, suspended five studies on its experimental leukemia and lymphoma medicine after two patient deaths.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.